H.C. Wainwright raised the firm’s price target on Hive Digital (HIVE) to $10 from $8 and keeps a Buy rating on the shares. The company reported ...

Fintel reports that on February 12, 2025, HC Wainwright & Co. downgraded their outlook for Inhibikase Therapeutics ...

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at HC ...

Femasys (NASDAQ:FEMY – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a report released on Tuesday,Benzinga reports. They presently have a $12.00 target price ...

H.C. Wainwright analyst Emily Bodnar raised the firm’s price target on AnaptysBio (ANAB) to $22 from $19 and keeps a Neutral rating on the shares after the company announced Phase 2b topline data from ...

H.C. Wainwright raised the firm’s price target on Coinbase (COIN) to $330 from $255 and keeps a Buy rating on the shares. President Donald ...

In this article, we are going to take a look at where Knightscope, Inc. (NASDAQ:KSCP) stands against the other AI stocks. In the latest news in AI, SoftBank Group CEO Masayoshi Son said that he has ...

Fintel reports that on February 7, 2025, HC Wainwright & Co. initiated coverage of Vertical Aerospace (NYSE:EVTL) with a Buy recommendation. As of January 28, 2025, the average one-year price ...

Fintel reports that on February 3, 2025, HC Wainwright & Co. initiated coverage of CRISPR Therapeutics (LSE:0VRQ) with a Buy recommendation. There are 575 funds or institutions reporting positions ...

In 2024 H.C. Wainwright also held the top position in PlacementTracker's Market League Tables for At-the-Market (ATM) Offerings representing 72 transactions. In addition to presently serving as ...

NEW YORK--(BUSINESS WIRE)--H.C. Wainwright & Co., LLC, announced its #1 Ranking by transaction volume for the calendar year of 2024, maintaining the Firm’s top position for 11 consecutive years ...